Drug resistance mechanism and treatment strategy for targeted therapy of melanoma

Drug resistance of targeted therapy gradually emerges in the treatment of melanoma. Currently known mechanisms of drug resistance include reactivation of mitogen-activated protein kinase (MAPK) pathway, activation of MAPK alternative pathway, effects of tumor microenvironment, and abnormal expression of microRNA. Through the combination of targeted drugs, immunological combination therapy and other strategies can delay the occurrence of drug resistance, thereby prolonging the survival of patients. Key words: Melanoma; Drug resistance, neoplasm; Targeted therapy